Cymbalta Approval History

Cymbalta is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of major depressive disorder, neuropathic pain associated with diabetic peripheral neuropathy, generalized anxiety disorder, fibromyalgia and chronic musculoskeletal pain.

FDA Approval History for Cymbalta

DateArticle
Nov  5, 2010Approval FDA Clears Cymbalta to Treat Chronic Musculoskeletal Pain
Nov 30, 2009Approval FDA Approves Cymbalta for Maintenance Treatment of Generalized Anxiety Disorder
Jun 16, 2008Approval FDA Approves Cymbalta for the Management of Fibromyalgia
Nov 30, 2007Approval FDA Approves Cymbalta for Maintenance Treatment of Major Depressive Disorder
Feb 26, 2007Approval FDA Approves Cymbalta for Treatment of Generalized Anxiety Disorder
Sep  7, 2004Approval FDA Approves Cymbalta for Neuropathic Pain Associated With Diabetes
Aug  4, 2004Approval FDA Approves Cymbalta for the Treatment of Depression
Jun 24, 2004FDA Extends Action Date for Cymbalta for Continued Analysis of Already-Submitted Data

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web5)